New hope for liver cancer patients when first immunotherapy fails
NCT ID NCT07324473
Summary
This study is testing a new three-drug combination for people with advanced liver cancer that initially responded to immunotherapy but has since started growing again. It aims to see if adding a new drug (Ivarmacitinib) to two existing ones can help control the cancer. The trial will enroll 65 patients to measure how well the tumors shrink and how long the treatment keeps the cancer in check.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.